J.P. Morgan has downgraded BioNTech SE (NASDAQ: BNTX), acknowledging the company's substantial cash reserves and limited downside potential.
The analysts Jessica Fye, Na Sun, and Nick Lenard expressed concerns over downward revisions in long-term estimates and potential delays in substantial pipeline outcomes, which could impede the stock's recovery.
The analysis emphasizes the shrinking expectations related to BioNTech's COVID-related business, which has contributed to the stock's struggle, with ongoing uncertainties likely to pose challenges ahead.
J.P. Morgan observes that if the ongoing trend in the United States regarding COVID-19 vaccine ...